Actinium Pharmaceuticals Inc
Suletud
1.14 -7.32
Ülevaade
Aktsiahinna muutus
24h
Min
1.12
Max
1.25
Sissetulek | 418K -5.5M |
|---|---|
Aktsiakasum | -0.18 |
Kasumimarginaal | -6,600 |
Töötajad | 25 |
EBITDA | 525K -5.7M |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +380% upside |
Järgmine tulemuste avaldamine | 6. aug 2026 |
|---|
Turukapital | 4.4M 42M |
|---|---|
Eelmine avamishind | 8.46 |
Eelmine sulgemishind | 1.14 |
Actinium Pharmaceuticals Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Actinium Pharmaceuticals Inc Prognoos
Hinnasiht
By TipRanks
380% tõus
12 kuu keskmine prognoos
Keskmine 6 USD 380%
Kõrge 9 USD
Madal 4 USD
Põhineb 3 Wall Streeti analüütiku instrumendi Actinium Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.
